Xtant Medical Holdings, Inc. filed a Form 8-K with the SEC on November 16, 2026, announcing its financial results for the third quarter of 2026 via a press release furnished as Exhibit 99.1.

Key Highlights

  • Reporting period: The filing covers financial results for the third quarter of 2026, announced on November 16, 2026.
  • Exchange and ticker: Xtant Medical Holdings, Inc. common stock (par value $0.000001 per share) trades on NYSE American under the symbol XTNT.
  • Non-GAAP measure disclosed: The company disclosed its use of non-GAAP adjusted EBITDA as a supplemental financial measure alongside GAAP results.
  • Adjusted EBITDA definition: The company defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense, interest expense (net), and tax benefit (expense), with further adjustments for specific items.
  • Excluded items: Adjustments include non-cash compensation, unrealized foreign currency translation gains or losses, write-off of distribution agreement deposit, divestiture/acquisition-related expenses and income, acquisition-related fair value adjustments, and separation-related expenses.
  • Results delivery: The full text of the financial results is contained in the press release furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Xtant Medical Furnishes Q3 2026 Earnings Press Release with Non-GAAP Disclosure

Xtant Medical Holdings, Inc. (NYSE American:XTNT) filed a current report on November 16, 2026, under Item 2.02 (Results of Operations and Financial Condition), disclosing its financial results for the third quarter of 2026. According to the filing, the full details of those results are contained in a press release furnished as Exhibit 99.1. The filing notes that the information in Item 2.02, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended."

The filing dedicates substantial space to explaining the company's use of non-GAAP adjusted EBITDA. According to the registrant, the company uses this measure "in making operating decisions because it believes this measure provides meaningful supplemental information regarding its core operational performance." The company stated it also uses the measure to inform decisions related to sales and marketing, research and development investment, and budgeting and spending allocations. The filing specifies that non-GAAP adjusted EBITDA is reconciled to net income (loss), described as the most directly comparable GAAP measure, within the press release.

The filing enumerates the categories of items excluded from non-GAAP adjusted EBITDA. These include non-cash compensation related to equity awards, unrealized foreign currency translation gains or losses, write-off of a distribution agreement deposit, divestiture and acquisition-related expenses and income related to transition services agreements, acquisition-related fair value adjustments, and separation-related expenses. The company stated that each exclusion is made because the relevant item is "not reflective of the Company's ongoing operating results." The filing also cautions that non-GAAP financial measures "are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies."

What Was Disclosed

Xtant Medical Holdings filed an 8-K on November 16, 2026, announcing Q3 2026 financial results through a furnished press release (Exhibit 99.1) and providing detailed definitions and rationale for its use of non-GAAP adjusted EBITDA as a supplemental performance measure.